Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Drug-drug interaction study of Ruzasvir and Bemnifosbuvir
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| BEM vs BEM + Ruzasvir n=16 | Experimental |
| |
| Ruzasvir vs Ruzasvir + BEM n=16 | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Cohort 1 BEM + Ruzasvir | Drug | Days 1 to 6 BEM under fasting conditions. Days 7 to 12 of BEM and Ruzasvir coadministered under fasting conditions. Days 13 to 18 of BEM and Ruzasvir coadministered under fed conditions |
| Measure | Description | Time Frame |
|---|---|---|
| Pharmacokinetics (PK) of BEM | Maximum plasma concentration (Cmax) and Area under the plasma concentration-time curve (AUC) | Days 6, 12, 18 |
| Pharmacokinetics (PK) of Ruzasvir | Maximum plasma concentration (Cmax) and Area under the plasma concentration-time curve (AUC) | Days 6, 12, 18 |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Atea Study Site | Québec | Montreal, Quebec | Canada |
Not provided
| ID | Term |
|---|---|
| C000621654 | ruzasvir |
| C000713067 | AT-511 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Cohort 2 Ruzasvir + BEM | Drug | Days 1 to 6 of Ruzasvir under fasting conditions. Days 7 to 12 of Ruzasvir and BEM coadministered under fasting conditions. Days 13 to 18 of Ruzasvir and BEM coadministered under fed conditions |
|
|